Trial Profile
Non-randomized Phase 2 Open-label Multicenter Study Determining the Response to Cabazitaxel in Metastatic Prostate Cancer (mCRPC) Patients With AR-V7 Positive Circulating Tumor Cells (CTCs): CARVE
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms CARVE
- 16 Aug 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 08 Dec 2015 New trial record